Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05314257
Collaborator
(none)
102
1
2
8
12.7

Study Details

Study Description

Brief Summary

Cardiac disease in pregnancy is a high-risk condition and a major cause of maternal mortality and morbidity. Although direct or immediate death due to cardiovascular disease is rare, it is an important indirect cause of maternal death worldwide, with an attributable rate of two deaths per 100,000 pregnancies. Cardiovascular physiological changes during pregnancy impose an additional load on the cardiovascular system of women with underlying heart disease which increases morbidity and mortality during pregnancy and at the time of delivery. Among cardiac diseases, Rheumatic Heart Disease is the commonest cardiac disease complicating pregnancy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Granisetron Hydrochloride
  • Other: 0.9% normal saline
Phase 2/Phase 3

Detailed Description

The subarachnoid block is the most used anesthesia technique for conducting a cesarean section. The incidence of hypotension following this procedure is as high as 20-40% in pregnant patients. Similarly, bradycardia is also commonly associated with post-SAB, and the reported incidence is around 13%. Spinal anesthesia results in sympathetic block leading to a decrease in systemic vascular resistance and hypotension. Hypotension caused by subarachnoid block is physiologically compensated by an increase in heart rate. However, if vagus nerve-mediated Bezold-Jarisch reflex gets stimulated, then the cardiac autonomic balance gets shifted towards the parasympathetic nervous system leading to bradycardia, which further precipitates hypotension.

Levobupivacaine is a highly potent long-acting local anesthetic with a comparatively slow onset of action. Compared to bupivacaine, it has a lower tendency to block deactivated cardiac sodium and potassium channels with a more rapid rate of dissociation. It has reduced cardiac toxicity on overdose intravenous administration due to its faster protein binding rate. Plain levobupivacaine is isobaric to CSF. One of its advantages is that it has a more expectable spread. Several studies have revealed the reduced occurrence of various side effects (such as nausea, vomiting, bradycardia, and hypotension) when levobupivacaine compared with bupivacaine for spinal anesthesia used for cesarean delivery. It has been suggested to use 12.5-13.5mg levobupivacaine for effective spinal anesthesia for cesarean delivery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section: A Randomized Clinical Trial
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group G

IV granisetron 1mg

Drug: Granisetron Hydrochloride
IV granisetron 1mg
Other Names:
  • granisetron
  • Placebo Comparator: Group C

    IV 5ml of 0.9% normal saline

    Other: 0.9% normal saline
    IV 5ml of 0.9% normal saline
    Other Names:
  • normal saline
  • Outcome Measures

    Primary Outcome Measures

    1. post-spinal hypotension, and bradycardia [24 hours postoperative]

      post-spinal hypotension, and bradycardia in rheumatic patients undergoing elective cesarean section

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Rheumatic female patients in the childbearing period scheduled for elective cesarean sections
    Exclusion Criteria:
    • Patients with eclampsia and pre-eclampsia history,

    • uncontrolled diabetes mellitus, morbid obesity,

    • coagulation abnormalities,

    • vertebral deformities, also patients who refused regional anesthesia,

    • having contraindications to spinal anesthesia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assiut governorate Assiut Egypt 715715

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ghada Mohammed AboelFadl, Principal investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05314257
    Other Study ID Numbers:
    • Granisetron
    First Posted:
    Apr 6, 2022
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022